UNSPSC 51401519: Ethyl loflazepate

This classification denotes a benzodiazepine with the molecular formula C18H14ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJB5FW9W9J, chemically known as 1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro but generally known as ethyl loflazepate, which bears US NIH Compound Identifier 3299. European Medicines Agency schedules Ethyl loflazepate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07290MIG.

UNSPSC 51401519 Ethyl loflazepate is a Commodity code that nominally designates a specific benzodiazepine pharmaceutical active ingredient, but recent state and local procurement activity under this code does not align with that narrow scope. Instead, the solicitations tagged to it reflect broader pharmaceutical procurement: naloxone and drug deactivation systems for community health, direct-to-manufacturer prescription program implementation, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The mismatch suggests either tagging inconsistency in the issuing systems or that the code is being used more broadly to cover pharmaceutical procurement categories rather than this specific compound. State and local issuing bodies soliciting under or near this code include county health departments, state HHS agencies, and cooperative purchasing organizations serving multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with contract terms of two years plus optional one-year renewal and FEMA funding compliance requirements. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions, requiring vendors to work through three authorized wholesalers and pay a 3 percent administrative fee. The code shows limited focused activity; the divergence between the nominal commodity and actual procurements warrants clarification before pursuing opportunities under this designation.